Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AXN-2510

Bispecific antibody · Antagonist of PD-L1 (CD274) and VEGF

Phase 1 Most advanced trial (none active)
1 Registered trials

What is AXN-2510?

AXN-2510 is a bispecific antibody that blocks PD-L1 and inhibits VEGF, combining immune checkpoint inhibition with anti-angiogenic activity. It is designed to enhance antibody-dependent cellular cytotoxicity against PD-L1-positive tumor cells. The drug is in development for solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
PD-L1 (CD274), VEGF
Mechanism
Antagonist of PD-L1 (CD274) and VEGF
Pathways
angiogenesis, immune checkpoint inhibition
Therapy area
Oncology
In trials of
TIL
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07159828 Phase 1 Solid Tumor, Adult Terminated TIL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor, Adult

Other drugs acting on CD274

Durvalumab FDA approved Acasunlimab Phase 3 AN4005 Phase 1 CDX-527 Phase 1 Cenopodlin Phase 1 CTX-8371 Phase 1 Enristomig Phase 1 Pumitamig Phase 2/3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.